Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab- or talquetamab-based triplets versus DRd in transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma
2023-503442-30-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
Phase 3, randomised trial of teclistamab, talquetamab, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and 12-month MRD-negative complete response. Planned start Oct 2022; status: authorised.
02
Drugs
teclistamabtalquetamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-503442-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503442-30-00.